Human LGALS9C knockout A549 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
LGALS9C KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon3 and 4 bp deletion in exon3 and 4 bp insertion in exon3 and 8 bp deletion in exon3.
View Alternative Names
Gal-9C, Galectin-9-like protein B, Galectin-9C, LGALS9C
- Sanger seq
Unknown
Sanger Sequencing - Human LGALS9C knockout A549 cell lysate (AB263244)
Allele-1 : 22 bp deletion in exon3
- Sanger seq
Unknown
Sanger Sequencing - Human LGALS9C knockout A549 cell lysate (AB263244)
Allele-3 : 4 bp deletion in exon3
- Sanger seq
Unknown
Sanger Sequencing - Human LGALS9C knockout A549 cell lysate (AB263244)
Allele-2 : 8 bp deletion in exon3
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LGALS9C influences immune response modulation highlighting its presence in immune cell function. It interacts with biologically significant partners often forming a complex with receptors like Tim-3 on T cells. This interaction can either promote cell death in certain contexts or drive anti-inflammatory responses. The involvement of LGALS9C in regulating the survival and function of these cells underlines its importance in maintaining homeostasis within the immune system.
Pathways
LGALS9C plays significant roles within immune signaling pathways including the Tim-3/Galectin-9 pathway. It also intersects with the apoptosis regulatory pathway influencing cellular outcomes during immune responses. LGALS9C interacts with proteins such as Tim-3 and PD-1 which share pathways that regulate immune responses and tolerance. The modulation of immune checkpoints places LGALS9C within a network of pathways that could influence therapy in chronic inflammation and cancer.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com